Clarient has announced the launch of a new gene mutation test, that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The test, called epidermal growth factor receptor (EGFR) mutation, has been validated as a laboratory-developed test.
EGFR activates an important pathway that leads to cell proliferation, lack of differentiation, and enhanced cell survival and gene transcription.
Ron Andrews, CEO of Clarient, said: Our new EGFR mutation test can be used as a predictive molecular biomarker to explain why a subset of patients with non-small cell lung cancer may respond to EGFR tyrosine kinase inhibitor (TKI) therapies.
This information can help pathologists and oncologists improve the overall management of this difficult disease, he added.